Arno Therapeutics, Inc. HomeAbout UsPipelineInvestor RelationsContact Us
Creating the next generation of cancer treatments
Investor & Media
Press ReleasesIn the NewsPublicationsEvents & PresentationsAnalyst Coverage
Stock InformationSEC FilingsGovernanceTransfer Agent

PRESS RELEASES ARCHIVE


2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017

2008 PRESS RELEASES

  • Jan. 28, 2008
    Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds more »
  • June 4, 2008
    Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger more »

  • June 5, 2008
    BioWorld Today - Arno Gets $18M Plus Market Access in Reverse Merger more »

  • July 16, 2008
    Arno Therapeutics Announces New Ticker Symbol more »

  • August 14, 2008
    Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer more »

  • August 18, 2008
    Arno Therapeutics Announces Second Quarter 2008 Financial Results more »

  • September 3, 2008
    Arno Therapeutics Announces Appointment of Roger G. Berlin, MD, as Chief Executive Officer and Director more »

  • October 30, 2008
    Arno Therapeutics Appoints William F. Hamilton to Board of Directors more »

  • November 3, 2008
    Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference more »

  • November 14, 2008
    Arno Therapeutics Announces Third Quarter 2008 Financial Results more »

2009 PRESS RELEASES

  • March 17, 2009
    FDA Accepts IND for Arno Therapeutics’ Pan-DAC/Akt Inhibitor, AR-42 more »
  • March 31, 2009
    Arno Therapeutics Reports 2008 Year-End Financial Results more »

  • May 4, 2009
    Arno Therapeutics to Deregister its Common Stock under the Exchange Act more »

  • May 11, 2009
    FDA Accepts Arno Therapeutics' IND for AR-12 a PDK1 Inhibitor That Blocks the PI3K/Akt Pathway more »

  • May 27, 2009
    Arno Therapeutics Announces Three Poster Presentations at ASCO Annual Meeting more »

  • July 23, 2009
    Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 (formerly DB-67) in Patients with Myelodysplastic Syndrome more »

  • August 27, 2009
    Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway more »

  • December 15, 2009
    Arno Therapeutics Announces Poster Presentation at ASH Annual Meeting Demonstrating Anti-Leukemic Stem Cell Activity of AR-42 more »

  • December 17, 2009
    Arno Therapeutics Announces Enrollment of First Patient in Phase II Study of AR-67 in Patients with Glioblastoma Multiforme (GBM) more »

2010 PRESS RELEASES

  • June 17, 2010
    Arno Therapeutics Announces Dosing of First Patient in a Phase I/IIa Study of AR-42, a broad spectrum histone and non-histone deacetylation inhibitor (pan-DAC) more »

  • September 13, 2010
    Arno Therapeutics, Inc. Raises $15 Million in Private Placement To Advance Clinical Development of Oncology Compounds more »

2011 PRESS RELEASES

  • April 28, 2011
    Arno Therapeutics Announces the Appointment of Mr. Glenn Mattes as President and Chief Executive Officer more »

  • June 23, 2011
    Arno Therapeutics Reports Positive Interim Results from Glioblastoma Study; Phase II Enrollment to Continue more »


  • June 27, 2011
    Arno Therapeutics Names Alexander Zukiwski, M.D., Vice President and Chief Medical Officer more »

2012 PRESS RELEASES

  • February 14, 2012
    Arno Therapeutics Announces Exclusive Licensing Agreement with Invivis Pharmaceuticals to Develop Cancer Drug more »

  • February 21, 2012
    Arno Therapeutics Receives Two Orphan-Drug Designations for AR-42 in Treatment of Central-Nervous-System Tumors more »

  • May 11, 2012
    Arno Therapeutics Announces Orphan-Drug Designation for AR-42 in Europe more »

  • June 7, 2012
    Arno Therapeutics Announces Additional Orphan-Drug Designations for AR-42 in Europe more »

  • November 9, 2012
    Arno Therapeutics Reports Progress in Development of Clinical Biomarkers to Support Treatment of Breast Cancer with Onapristone more »

  • November 27, 2012
    Arno Therapeutics Completes $12.7 Million Financing more »

  • December 5, 2012
    Arno Therapeutics Reports Findings of New Diagnostic Technique the Potential to Identify Patients with Cancer Who May Respond to Treatment with Onapristone more »

  • December 19, 2012
    Arno Therapeutics Completes $14.9 Million Financing To Advance Lead Clinical Compounds more »

2013 PRESS RELEASES

  • January 31, 2013
    Arno Therapeutics, Inc. Appoints Randy Thurman to the Board of Directors more »

  • March 19, 2013
    Arno Therapeutics Engages The Ruth Group for Investor Relations and Public Relations Counsel more »

  • April 8, 2013
    Arno Therapeutics Reports Activated Progesterone Receptors Predictive of Response to Onapristone
    Data Presented Today at AACR Annual Meeting 2013 more »

  • May 10, 2013
    Arno Therapeutics to Collaborate with Clarient for Development of Diagnostic Test more »

  • May 15, 2013
    Arno Therapeutics to Present Positive, New Data Supporting the Potential of Onapristone in Endometrial and Breast Cancers at ASCO 2013 Annual Meeting more »

  • June 3, 2013
    Arno Therapeutics to Collaborate With Veridex on Development of Diagnostic Test more »

  • August 21, 2013
    Arno Therapeutics Initiates Pharmacokinetic Study for Onapristone Following Regulatory Acceptance - Biotrial to Serve as Contract Research Organization for Paris-Based Trial more »

  • September 9, 2013
    Arno Therapeutics Submits IMPD to French Health Authority to Initiate Phase I Trial of Onapristone in PR Positive Tumors - Trial to Determine Recommended Dose for Phase II Study more »

  • September 28, 2013
    Arno Therapeutics to Present Data Validating Target Biomarker at European Cancer Congress 2013
    - Underscores role of anti-progestins Supports further evaluation of onapristone and development of companion diagnostic Expands on findings presented at ASCO 2013 -more »

  • October 29, 2013
    Arno Therapeutics Data Supports Further Evaluation of Onapristone in Prostate Cancer
    - Supports further evaluation of onapristone in castrate-resistant prostate cancer with presence of activated progesterone receptor - more »

  • October 30, 2013
    Arno Therapeutics Completes $30.7 Million Financing, Recapitalization and 1-for-8 Reverse Stock Split more »

  • November 18, 2013
    Arno Therapeutics Adds Steven Rubin, EVP of OPKO Health, Inc., as Board Observer more »

  • December 14, 2013
    Arno Therapeutics to Present Data on Two Potential Predictive Biomarkers at the San Antonio Breast Cancer Symposium 2013 more »

2014 PRESS RELEASES

  • January 7, 2014
    Arno Therapeutics Selects Leica Biosystems to Develop Companion Diagnostic for Targeted Oncology Therapy Onapristone more »

  • January 9, 2014
    Arno Therapeutics to Present at Biotech Showcase 2014 more »

  • January 13, 2014
    Arno Therapeutics Expands Management Team with Additions of Two Scientific Leaders more »

  • Jan 21, 2014
    Arno Therapeutics Enrolls First Patient in a Phase I Trial to Evaluate Lead Compound Onapristone in Progesterone Receptor Positive Solid Tumors more »

  • Feb 27, 2014
    Arno Therapeutics Appoints Lawrence A. Kenyon Chief Financial Officer more »

  • March 4, 2014
    Arno Therapeutics Granted Exclusive License for Oncology Diagnostic Technique by University of Minnesota more »

  • March 5, 2014
    Arno Therapeutics to Present at 26th Annual ROTH Conference more »

  • March 24, 2014
    Arno Therapeutics Board of Directors Appoints Randy Thurman as Vice Chairman more »

  • March 26, 2014
    Arno Therapeutics to Present Three New Studies Supporting the Clinical Development of Onapristone at AACR Annual Meeting 2014 more »

  • April 1, 2014
    Arno Therapeutics Reports 2013 Financial Results and Provides Update on Strategic and Operational Milestones more »

  • April 7, 2014
    Arno Therapeutics Enrolls First Patient in a Phase I/II Trial Evaluating Onapristone in Men with Advanced Castration-Resistant Prostate Cancer more »

  • May 5, 2014
    Arno Therapeutics Announces Clinical Abstracts Accepted at 2014 ASCO Annual Meeting more »

  • May 14, 2014
    Arno Therapeutics to Outline Two Phase I Studies Evaluating Onapristone in Men's and Women's Cancers at 2014 ASCO Annual Meeting more »

  • May 15, 2014
    Arno Therapeutics Reports First Quarter 2014 Financial and Business Update more »

  • May 29, 2014
    Arno Therapeutics to Present at the Jefferies 2014 Global Healthcare Conference more »

  • July 18, 2014
    Arno Therapeutics, Inc. Appoints Alexander Zukiwski, M.D. as Interim Chief Executive Officer and Mr. Lawrence Kenyon as Chief Operating Officer more »

  • Aug. 14, 2014
    Arno Therapeutics Reports Second Quarter 2014 Financial and Business Update more »

  • Sept. 8, 2014
    Arno Therapeutics to Present at Upcoming Investor Conferences more »

  • Sept. 18, 2014
    Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014 more »

  • Sept. 30, 2014
    Arno Therapeutics to Present at the 13th Annual BIO Investor Forum more »

  • Oct. 23, 2014
    Arno Therapeutics to Present Encouraging Data from Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat more »

  • Oct. 27, 2014
    Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage more »

  • Oct. 29, 2014
    Arno Therapeutics' Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference more »

  • November 14, 2014
    Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update more »

  • November 24, 2014
    Arno Therapeutics to Present at LD Micro Conference 2014 more »

  • December 4, 2014
    Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors more »
    Dr. Zukiwski Named Chief Executive Officer

  • December 9, 2014
    Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014 more »

  • December 10, 2014
    Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors more »

2015 PRESS RELEASES

  • January 8, 2015
    Arno Therapeutics to Present at 11th Annual Noble Equity Conference more »

  • March 24, 2015
    New Data Supporting Arno Therapeutics’ HDAC inhibitor AR-42 Published in The Journal of Urology more »

  • March 31, 2015
    Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update more »

  • April 13, 2015
    Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015 more »

  • April 21, 2015
    Arno Therapeutics to Present Promising Data from Phase I Trial of Onapristone at AACR Annual Meeting 2015 more »

  • April 29, 2015
    Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015 more »

  • April 30, 2015
    Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases more »

  • May 7, 2015
    Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone more »

  • May 13, 2015
    Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015 more »

  • May 14, 2015
    Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 more »

  • May 28, 2015
    Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research more »

  • June 3, 2015
    Arno Therapeutics Announces Cooperative Research and Development Agreement with US Army Medical Research Institute of Infectious Diseases to Test Antiviral Activity of AR-12 more »

  • June 4, 2015
    Arno Therapeutics Announces Issuance of First Onapristone Patent more »

  • Augus 15, 2015
    Arno Therapeutics Announces Issuance of First Onapristone Patent more »

  • August 18, 2015
    Arno Therapeutics Receives Authorization to Proceed with Modified Phase I/II Trial Evaluating Onapristone in Prostate Cancer more »

  • September 1, 2015
    Arno Therapeutics to Present at 17th Annual Rodman & Renshaw Conference more »

  • September 14, 2015
    AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 more »

  • September 19, 2015
    Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists (AAPS) Annual Exposition more »

  • September 19, 2015
    Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs more »

  • September 24, 2015
    Arno Therapeutics' AR-13 Data Show Promise as Potential New Therapeutic Option for Cystic Fibrosis Patients with Serious Bacterial Infections more »

  • September 25, 2015
    Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference more »

  • October 21, 2015
    Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains more »

  • October 29, 2015
    Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis more »

  • November 16, 2015
    Arno Therapeutics Reports Third Quarter 2015 Financial Results and Business Update more »

2016 PRESS RELEASES

  • January 13, 2016
    Arno Therapeutics Completes $7.4 Million Common Stock Financing more »

  • March 21, 2016
    Arno Therapeutics Advances Phase I/II Trial Evaluating Onapristone in Prostate Cancer to Phase II more »

  • March 30, 2016
    Arno Therapeutics Reports Fourth Quarter and Full Year 2015 Financial Results and Business Update more »

  • April 19, 2016
    Arno Therapeutics to Focus Clinical Developmental Activities on Advanced Prostate Cancer in First-of-its-Kind Phase II Study of Onapristone in Combination with ZYTIGA® more »

  • May 16, 2016
    Arno Therapeutics Reports First Quarter 2016 Financial and Business Update
    Read

  • August 16, 2016 - Arno Completes $2.8 Million Private Placement
    Read

  • August 19, 2016 - Arno Therapeutics Reports Second Quarter 2016 Financial and Business Update
    Read

  • Novermber 14, 2016 - Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update
    Read

  • December 21, 2016 - Arno Therapeutics Reports Third Quarter 2016 Financial and Business Update
    Read




Arno Therapeutics, Inc.
200 Route 31 North
Suite 104
Flemington, NJ 08822

(862) 703-7170 Main
(908) 237-0071 Fax

Email